TECHNOLOGIES

ANTI-Δ42PD1 BLOCKING ANTIBODY PLATFORM

Patents: US11236144B2/CN105431449B

 

Introduction

 

The PD-1 isoform is a unique isoform of the immune checkpoint PD-1 molecule. As opposed to the immunoregulatory function of the wildtype PD-1 molecule, the PD-1 isoform promotes pro-inflammatory reactions.

 

PD-1 isoform blockade results in the suppression of pro-inflammatory reactions

Our patented anti-PD-1 isoform antibody platform could effectively block the interaction of PD-1 isoform with its unique cognate receptor to substantially suppress the release of pro-inflammatory molecules, resulting in the reduction of inflammation-mediated pathological anomalies.

 

PD-1 isoform blockade in tumour suppression

Inflammation induced by the PD-1 isoform can lead to the exhaustion and loss of function of T cells, preventing the elimination of tumour cells. The potential therapeutic efficacy of our technology to reverse T cell exhaustion to treat cancers is currently being evaluated.

 

References:

Cheng L, Tang X, Liu L, Peng J, Nishiura K, Cheung AKL, et al. Monoclonal antibodies specific to human Δ42PD1: A novel immunoregulator potentially involved in HIV-1 and tumor pathogenesis. mAbs. 2015 Feb 18;7(3):620–9. Available from: https://doi.org/10.1080/19420862.2015.1016695

Cheung AKL, Kwok HY, Huang Y, Chen M, Mo Y, Wu X, et al. Gut-homing Δ42PD1+Vδ2 T cells promote innate mucosal damage via TLR4 during acute HIV type 1 infection. Nature Microbiology. 2017 Aug 14;2(10):1389–402. Available from: https://doi.org/10.1038/s41564-017-0006-5 

Liu L, Fang J, Gong R, Peng J, Cao T, Peng Q, et al. Isoformic PD-1 impedes B cell activation and function in HIV-1 infection. Cell Reports. 2025 Oct 1;44(10):116341. Available from: https://doi.org/10.1016/j.celrep.2025.116341 

Tan Z, Chiu MS, Yang X, Yue M, Cheung TT, Zhou D, et al. Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients. Gut. 2022 Nov 30;72(8):1568–80. Available from: https://doi.org/10.1136/gutjnl-2022-327133